基托桑纳米颗粒可以提高米尔特福辛对抗阿坎萨摩埃巴菌的有效性
Alireza Latifi1, Fariba Esmaeili2, Mehdi Mohebali1,3
1Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
PLoS neglected tropical diseases
|March 25, 2024
概括
含有米尔特福辛的奇托桑纳米颗粒 (MF-CS-NP) 显示出对阿坎萨摩巴角膜炎 (AK) 寄生虫的效果有所提高. 这种纳米配方降低了米尔特福辛的毒性,为治疗这种危害视力的角膜感染提供了一个有前途的策略.
科学领域:
- 眼科医生 眼科 眼科
- 纳米技术 纳米技术
- 传染性疾病 传染性疾病
背景情况:
- 阿坎萨摩巴角膜炎 (AK) 是一种严重的角膜感染,具有显著的视力损伤风险.
- 早期治疗对于AK的视觉结果至关重要.
- 基托桑纳米颗粒在眼部感染中提供了增强药物递送的潜力.
研究的目的:
- 为Acanthamoeba治疗合成和评估含有米尔特素的奇托桑纳米颗粒 (MF-CS-NP).
- 在体外评估MF-CS-NP对Acanthamoeba的疗效和安全性.
- 调查纳米基托桑作为眼部药物输送的载体的潜力.
主要方法:
- 使用离子凝制备了含有米尔特福辛的奇托桑纳米颗粒 (MF-CS-NP).
- 粒子大小,泽塔潜力和药物释放概况的特征.
- 细胞毒性,血液溶解活性,眼部刺激和氨杀菌活性 (IC50) 在体外和体内都进行了评估.
主要成果:
- MF-CS-NP表现出持续的药物释放,具有最佳粒子大小 (46.61 nm) 和泽塔电位 (21.8 mV).
- 与自由的miltefosine相比,MF-CS-NP的细胞毒性和眼部刺激显著降低.
- 这种纳米配方显示出对阿坎萨摩巴和囊的增强的杀活性.
结论:
- 在治疗Acanthamoeba角膜炎方面,MF-CS-NP比自由的miltefosine更有效,毒性更低.
- 纳米基托桑作为一种有效的载体,降低了米尔特福辛的细胞毒性.
- 需要进一步的动物研究来探索MF-CS-NP在眼部药物输送中的临床应用.
相关概念视频
Microbial Corrosion
Microbiologically Influenced Corrosion (MIC) is a significant form of material degradation caused by the metabolic activities of microorganisms. This phenomenon poses substantial challenges across various industries, including oil and gas, maritime, and water treatment sectors.MIC occurs when microorganisms, such as bacteria, archaea, and fungi, colonize metal surfaces, forming biofilms that alter the local electrochemical environment. These biofilms can lead to the production of corrosive...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


